Gastro Florida

Clearwater, Florida 33765

3 studies enrolling now · 32 studies all time

What they study most

Biliary Cirrhosis, Primary, C. Diff Infection, C.Difficile Diarrhea, CDI, Clostridioides Difficile, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Clostridium Difficile, Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence, Clostridium Difficile Infections, Colitis, Ulcerative

Studies at this site

• VE303 for Prevention of Recurrent Clostridioides Difficile Infection — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting — Recruiting now
• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) — Completed
• A Longitudinal Observational Study of the Natural History and Management of Patients With HCC — Running, not enrolling
• Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease — Running, not enrolling
• A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis — Completed
• An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice — Stopped early
• Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) — Completed
• Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year — Completed
• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) — Completed
• A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease — Stopped early
• Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease — Completed
• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) — Completed
• Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis — Completed
• Triple Combination Therapy in High Risk Crohn's Disease (CD) — Completed
• Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection — Completed
• Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis — Completed
• Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis — Completed
• A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI) — Completed
• Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) — Stopped early
• AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis — Completed
• Diabetic Gastroparesis Study 05 — Stopped early
• Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis — Completed
• Direct Acting Antiviral-Post Authorization Safety Study — Completed
• Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306) — Stopped early
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis — Stopped early